<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983200</url>
  </required_header>
  <id_info>
    <org_study_id>KY20190530-04</org_study_id>
    <nct_id>NCT03983200</nct_id>
  </id_info>
  <brief_title>Effect of Rotating Magnetic Therapy on Diabetic Peripheral Neuropathy</brief_title>
  <official_title>Effect of Rotating Magnetic Therapy on Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Majianhua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the eï¬€ect of Rotating Magnetic Therapy on Diabetic
      Peripheral Neuropathy using Nerve conduction velocity examination.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nerve conduction velocity examination</measure>
    <time_frame>1 month</time_frame>
    <description>the change of Nerve conduction velocity examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MNSI</measure>
    <time_frame>1 month</time_frame>
    <description>Michigan Neuropathy Screening Instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated serum albumin</measure>
    <time_frame>1 month</time_frame>
    <description>the change of Glycosylated serum albumin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Mecobalamine 0.5mg, tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotating Magnetic Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rotating Magnetic Therapy 30min,bid + Mecobalamine 0.5mg, tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rotating Magnetic Therapy</intervention_name>
    <description>Rotating Magnetic Therapy 30min, bid</description>
    <arm_group_label>Rotating Magnetic Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mecobalamin</intervention_name>
    <description>mecobalamine 0.5mg,tid</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Rotating Magnetic Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1. Volunteer to participate and sign informed consent prior to the study 2. Patients with
        type 2 diabetes, who met WHO1999 diagnostic criteria, had diabetes distal symmetrical
        multiple neuropathy (1) clear history of diabetes; (2) neuropathy at or after diagnosis of
        diabetes;(3) clinical manifestations and signs are consistent with DPN;(4) have clinical
        symptoms (pain, numbness, paresthesia, etc.), 5 examination (ankle reflex, acupuncture pain
        sense, vibration sense, pressure sense, temperature sense) any 1 abnormal;If there were no
        clinical symptoms, 2 of the 5 examinations were abnormal.(5) exclude other causes of
        neuropathy).

        3. HbA1c&lt;7.5%, the hypoglycemic regimen was stable for 3 months 4. No acute complications,
        such as diabetic ketoacidosis, diabetic hyperosmolar syndrome, etc.

        Exclusion Criteria:

          -  1. Patients with foreign metal bodies or pacemakers 2. Patients with a history of
             surgery at magnetic therapy sites within one year 3. Patients with obvious discomfort
             to magnetic therapy 4. Patients with bleeding or bleeding tendency 5. Patients with
             acute complications such as diabetic ketoacidosis 6. Impaired liver and kidney
             function with ALT 2.5 times higher than the upper limit of normal value;Serum
             creatinine was 1.3 times higher than the upper limit of normal 7. History of drug
             abuse and alcohol dependence in the past 5 years 8. Systemic hormone therapy was used
             in the last three months 9. Patients with infection and stress within 4 weeks 10.
             Patients who are pregnant, breast-feeding, or intending to become pregnant. 11. Any
             other obvious conditions or co-existing diseases determined by the researcher: such as
             severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors,
             other pancreatic diseases, patients with a history of mental illness, or severe
             wasting diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Majianhua</investigator_full_name>
    <investigator_title>Director, Head of Endocrinology department, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

